Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Assa Abloy Ab

Disc Medicine, Inc.

Yale University

Abbott Gmbh & Co Kg

Bernhard K Mueller

Andreas Popp

Jennifer Maria Perez

Martin Schmidt

Eve H Barlow

Philip D Bardwell

Tariq Ghayur

Nicole Teusch

Achim Moeller

Mario Mezler

Yuliya Kutskova

John Memmott

Reinhold Mueller

Lili Huang

Axel Meyer

Chung-Ming Hsieh

Matthias Mann

Mary Leddy

Philippe Patrick Monnier

Paolo Macchi

Friedrich Bonhoeffer

Bernd Stahl

Wilfried Hornberger

Helmut Mack

Anil Vasudevan

Adrian Hobson

David J Hawksworth

Robert N Ziemann

Daryl Richard Sauer

Larry G Birkenmeyer

Susan E Brophy

Ryan G Keddy

Stephen M Strittmatter

Frank C Grenier

Steven Robinette

Elaine Marie Brate

Gangamani S Beligere

Dominique Bonafoux

Alfred Hahn

Juergen Hofmann

Michael F Jarvis

Bertrand Roland

Jens S Andersen

Steve Swann, Jr

Jens S Anderson

Volker Krisch

Hardy Bismark

Jürgen Hofmann

Lutz Deitinghoff

John Quisel

Brian MacDonald

Maria Beconi

Shamila Manoj

Mary R Leddy

Phillip D Bardwell

Philippe P Monnier

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.

Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.

Composition and method for the diagnosis and treatment of iron-related disorders

Provided herein are anti-Repulsive Guidance Molecule a (RGMa) antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.

Antibodies that bind to repulsive guidance molecule A (RGMA)

The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.

Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Antibodies against the RGM A protein and uses thereof

Growing community of inventors

Neustadt, Germany

Bernhard K Mueller